Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); Q4 Review: Pimavanserin Study 020 Results Expected in Late 3Q12
Go back to Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); Q4 Review: Pimavanserin Study 020 Results Expected in Late 3Q12| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 28.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.24 | 52 Week High | $42.49 | |||
| Open | $28.24 | 52 Week Low | $16.64 | |||
| Day High | $28.24 | P/E | N/A | |||
| Day Low | $28.24 | EPS | $-0.42 | |||
| Volume | 11,406 | |||||
